You are using an older browser version. Please use a supported version for the best MSN experience.

Not surprising Allergan is getting acquired now, says Mizuho managing director

AbbVie is buying Allergan for $188.24 per share, at a premium of almost 45 percent. Mizuho analyst Irina Koffler joins 'Squawk Box' to discuss the merger and Allergan CEO's track record.

UP NEXT

UP NEXT

Recent Videos

Featured Partners

image beaconimage beaconimage beacon